Skip to main content

Advertisement

Table 5 Results of the scenario analyses

From: Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Scenario ΔQALY ΔCosts ICER
Base case values
 - 5-grass tablet vs. allergoid mix 0.036 € 458 € 12,593
 - 5-grass tablet vs. symptomatic tx 0.081 € 1,385 € 17,007
Scenario analysis 1: 100% Lump sums
 - 5-grass tablet vs. allergoid mix 0.036 € 546 € 15,025
 - 5-grass tablet vs. symptomatic tx 0.081 € 1,362 € 16,723
Scenario analysis 2: 100% Public to private (ambulatory)
 - 5-grass tablet vs. allergoid mix 0.036 € 305 € 8,400
 - 5-grass tablet vs. symptomatic tx 0.081 € 1,414 € 17,367
Scenario analysis 3: Societal perspective
 - 5-grass tablet vs. allergoid mix 0.036 € 339 € 9,327
 - 5-grass tablet vs. symptomatic tx 0.081 € 784 € 9,634
Scenario analysis 4: Changing utilities
 - 5-grass tablet vs. allergoid mix 0.026 € 458 € 17,531
 - 5-grass tablet vs. symptomatic tx 0.131 € 1,385 € 10,557
Scenario analysis 5: Shorter pollen season
 - 5-grass tablet vs. allergoid mix 0.024 € 266 € 10,966
 - 5-grass tablet vs. symptomatic tx 0.055 € 1,198 € 21,918